Latest Stocks: K Peony Yu Sells 5,000 Shares of FibroGen Inc (FGEN) Stock

Latest Stocks: K Peony Yu Sells 5,000 Shares of FibroGen Inc (FGEN) Stock

FibroGen Inc (NASDAQ:FGEN) insider K Peony Yu sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 10th. The stock was sold at an average price of $26.38, for a total transaction of $131,900.00. Following the sale, the insider now directly owns 227,346 shares in the company, valued at $5,997,387.48. The sale was disclosed in a legal filing with the SEC, which is available through this link.

K Peony Yu also recently made the following trade(s):

Shares of FibroGen Inc (NASDAQ:FGEN) opened at 28.70 on Tuesday. The company’s market capitalization is $2.01 billion. The stock has a 50 day moving average of $27.27 and a 200-day moving average of $24.54. FibroGen Inc has a one year low of $14.50 and a one year high of $29.00. FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. The business had revenue of $26.89 million for the quarter, compared to analysts’ expectations of $26.02 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. On average, equities analysts forecast that FibroGen Inc will post ($1.81) earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its position in FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after buying an additional 504 shares in the last quarter. Rothschild Asset Management Inc. boosted its position in FibroGen by 0.5% in the first quarter. Rothschild Asset Management Inc. now owns 186,005 shares of the biopharmaceutical company’s stock valued at $4,585,000 after buying an additional 959 shares in the last quarter. OppenheimerFunds Inc. boosted its position in FibroGen by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 356,236 shares of the biopharmaceutical company’s stock valued at $8,781,000 after buying an additional 1,066 shares in the last quarter. Algert Global LLC boosted its position in FibroGen by 6.4% in the first quarter. Algert Global LLC now owns 24,322 shares of the biopharmaceutical company’s stock valued at $600,000 after buying an additional 1,466 shares in the last quarter. Finally, American International Group Inc. boosted its position in shares of FibroGen by 7.1% in the first quarter. American International Group Inc. now owns 32,248 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 2,134 shares during the period. Institutional investors and hedge funds own 47.74% of the company’s stock. Separately, Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $37.50.

Receive News & Ratings for FibroGen Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for FibroGen Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment